Presentation is loading. Please wait.

Presentation is loading. Please wait.

JQ1 directly represses the promoter activities of BRCA1 and RAD51

Published byHelga Schumacher Modified over 6 years ago

Similar presentations

Presentation on theme: "JQ1 directly represses the promoter activities of BRCA1 and RAD51"— Presentation transcript:

1 Fig. 6. JQ1 directly represses the promoter activities of BRCA1 and RAD51.
JQ1 directly represses the promoter activities of BRCA1 and RAD51. (A and B) BRD2/3/4 binding pattern in the BRCA1 (A) or RAD51 (B) promoter regions in VCaP cells treated with DMSO or JQ1. Bottom: Illustrations of BRCA1 promoter–luciferase (Luc) (A) and RAD51 promoter–Luc (B) reporters, in which BRCA1 or RAD51 promoter containing the BRD2/3/4 binding region was cloned into pGL3. (C and D) Quantification of the amount of BRCA1 (C) or RAD51 (D) promoter bound to BRD2/3/4 in MDA-MB-231 cells treated with DMSO or JQ1. Statistical analysis by Student’s t test, *P < 0.05; n = 3. Error bars represent means ± SD. IgG, immunoglobulin G. (E and F) Luciferase reporter assay of the activities of the BRCA1 (E) and RAD51 (F) core promoter reporters in MDA-MB-231, OVCAR10, and VCaP cells treated with DMSO, JQ1, olaparib, or JQ1 combined with olaparib. Statistical analysis by Student’s t test, *P < 0.05; n = 3. Error bars represent means ± SD. (G and H) Luciferase reporter assay of the activities of the BRCA1 (G) and RAD51 (H) core promoter reporters in MDA-MB-231, OVCAR10, and VCaP cells treated with individual siRNAs targeting BRD2/3/4 or pooled siRNAs. Statistical analysis by Student’s t test, *P < 0.05; n = 3. Error bars represent means ± SD. Lu Yang et al., Sci Transl Med 2017;9:eaal1645 Published by AAAS

Download ppt "JQ1 directly represses the promoter activities of BRCA1 and RAD51"

Similar presentations

A B C D Rao et al., 2012; Supplementary Figure S1 p = 0.03 p = NS

A B C D Rao et al., 2012; Supplementary Figure S1 p = 0.03 p = NS
Fig. 8. Recurrent copy number amplification of BRD4 gene was observed across common cancers. Recurrent copy number amplification of BRD4 gene was observed.

Fig. 8. Recurrent copy number amplification of BRD4 gene was observed across common cancers. Recurrent copy number amplification of BRD4 gene was observed.
Fig. 4. PVSRIPO infection of DCs is sublethal, is marginally productive, and induces sustained proinflammatory cytokine production. PVSRIPO infection of.

Fig. 4. PVSRIPO infection of DCs is sublethal, is marginally productive, and induces sustained proinflammatory cytokine production. PVSRIPO infection of.
Fig. 1. Generation of ERY974. Generation of ERY974. (A) Schematic illustration of ERY974 structure and the introduced mutations. The two Fab arms share.

Fig. 1. Generation of ERY974. Generation of ERY974. (A) Schematic illustration of ERY974 structure and the introduced mutations. The two Fab arms share.
Fig. 6. AZD6738 induces DNA damage and apoptosis and exhibits antitumor efficacy in xenograft models of high-risk medulloblastoma and neuroblastoma. AZD6738.

Fig. 6. AZD6738 induces DNA damage and apoptosis and exhibits antitumor efficacy in xenograft models of high-risk medulloblastoma and neuroblastoma. AZD6738.
Differentiation of AZD4785 from MAPK pathway inhibitors in vitro

Differentiation of AZD4785 from MAPK pathway inhibitors in vitro
Fig. 6. dAST directly from clinical samples using dPCR and dLAMP for quantification. dAST directly from clinical samples using dPCR and dLAMP for quantification.

Fig. 6. dAST directly from clinical samples using dPCR and dLAMP for quantification. dAST directly from clinical samples using dPCR and dLAMP for quantification.
Fig. 1. Potent and selective down-regulation of KRAS mRNA and protein by AZD4785 in vitro and in vivo. Potent and selective down-regulation of KRAS mRNA.

Fig. 1. Potent and selective down-regulation of KRAS mRNA and protein by AZD4785 in vitro and in vivo. Potent and selective down-regulation of KRAS mRNA.
Dual-Luciferase Activation Assay with Potential Targets of ZmbZIP22.

Dual-Luciferase Activation Assay with Potential Targets of ZmbZIP22.
Fig. 5. Circulating PPi concentration does not correlate with severity of calcification phenotype in mice. Circulating PPi concentration does not correlate.

Fig. 5. Circulating PPi concentration does not correlate with severity of calcification phenotype in mice. Circulating PPi concentration does not correlate.
A FOXO3a-BIM cascade mediates sensitivity to PARP and MEK inhibition

A FOXO3a-BIM cascade mediates sensitivity to PARP and MEK inhibition
BET inhibition and depletion repress the expression of BRCA1 and RAD51

BET inhibition and depletion repress the expression of BRCA1 and RAD51
Fig. 2. Pharmacologic inhibition of ALK impairs STING activation.

Fig. 2. Pharmacologic inhibition of ALK impairs STING activation.
Fig. 4. Bexarotene promotes PPARδ activation of target genes in mouse brain and muscle. Bexarotene promotes PPARδ activation of target genes in mouse brain.

Fig. 4. Bexarotene promotes PPARδ activation of target genes in mouse brain and muscle. Bexarotene promotes PPARδ activation of target genes in mouse brain.
Fig. 2. dAST using dPCR is robust to the presence of high concentrations of commensal bacteria due to the specificity of NA amplification. dAST using dPCR.

Fig. 2. dAST using dPCR is robust to the presence of high concentrations of commensal bacteria due to the specificity of NA amplification. dAST using dPCR.
Fig. 4. Biomechanical properties of treated tibiae.

Fig. 4. Biomechanical properties of treated tibiae.
Fig. 1. Schematic representation of the MANO method.

Fig. 1. Schematic representation of the MANO method.
Analysis of brain and spinal cord of treated Gaa−/− mice and controls

Analysis of brain and spinal cord of treated Gaa−/− mice and controls
Fig. 1. PARPi and MEKi induce inverse adaptive responses.

Fig. 1. PARPi and MEKi induce inverse adaptive responses.
Fig. 3. BET inhibition reduces homologous recombination.

Fig. 3. BET inhibition reduces homologous recombination.

Similar presentations

Ads by Google